Key Aspects of the Novartis Compound Collection Enhancement Project for the Compilation of a Comprehensive Chemogenomics Drug Discovery Screening Collection

Author(s): Edgar Jacoby, Ansgar Schuffenhauer, Maxim Popov, Kamal Azzaoui, Benjamin Havill, Ulrich Schopfer, Caroline Engeloch, Jaroslav Stanek, Pierre Acklin, Pascal Rigollier, Friederike Stoll, Guido Koch, Peter Meier, David Orain, Rudolph Giger, Jurgen Hinrichs, Karine Malagu, Jurg Zimmermann, Hans- Joerg Roth

Journal Name: Current Topics in Medicinal Chemistry

Volume 5 , Issue 4 , 2005

Become EABM
Become Reviewer


The NIBR (Novartis Institutes for BioMedical Research) compound collection enrichment and enhancement project integrates corporate internal combinatorial compound synthesis and external compound acquisition activities in order to build up a comprehensive screening collection for a modern drug discovery organization. The main purpose of the screening collection is to supply the Novartis drug discovery pipeline with hit-to-lead compounds for todays and the futures portfolio of drug discovery programs, and to provide tool compounds for the chemogenomics investigation of novel biological pathways and circuits. As such, it integrates designed focused and diversity-based compound sets from the synthetic and natural paradigms able to cope with druggable and currently deemed undruggable targets and molecular interaction modes. Herein, we will summarize together with new trends published in the literature, scientific challenges faced and key approaches taken at NIBR to match the chemical and biological spaces.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [397 - 411]
Pages: 15
DOI: 10.2174/1568026053828376
Price: $65

Article Metrics

PDF: 29